Can you take Pemigatinib with Rescriptor?
1 drug interaction and 6 additional warnings found for the following 2 drugs:
- pemigatinib
- Rescriptor (delavirdine)
Drug interactions
Major drug interactions
Major:
delavirdine pemigatinib
Applies to: Rescriptor (delavirdine) and pemigatinib
Delavirdine may increase the blood levels of pemigatinib. This may increase the frequency and severity of serious side effects such as elevated phosphate levels in the blood (which can eventually lead to low blood calcium levels; calcium deposits in the skin, muscles, and other tissues; anemia; muscle cramps; seizures; and irregular heart rhythm), eye and vision problems, joint pain, mouth sores and inflammation, hair loss, diarrhea, nausea, vomiting, and constipation. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Major food/lifestyle interactions
Major:
pemigatinib Food/Lifestyle
Applies to: pemigatinib
Pemigatinib may be taken with or without food. Do not consume grapefruit, grapefruit juice, or any supplements that contain grapefruit extract during treatment with pemigatinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of pemigatinib. This may increase the frequency and severity of serious side effects such as elevated phosphate levels in the blood (which can eventually lead to low blood calcium levels; calcium deposits in the skin, muscles, and other tissues; anemia; muscle cramps; seizures; and irregular heart rhythm), eye and vision problems, joint pain, mouth sores and inflammation, hair loss, diarrhea, nausea, vomiting, and constipation. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Disease interactions
5 potential interactions Applies to: 4 conditions, including Liver Disease, Visual Defect/Disturbance, Renal Dysfunction, and Achlorhydria.
Achlorhydria
Moderate:
Rescriptor
The delavirdine in Rescriptor has a moderate potential interaction with Achlorhydria.
Patients with achlorhydria should take delavirdine with an acidic beverage such as orange or cranberry juice, presumably to improve absorption. Although the effects of acidic beverages on delavirdine absorption have not been studied, delavirdine is known to be poorly soluble when pH is greater than 3.
Liver Disease
Moderate:
pemigatinib
Pemigatinib has a moderate potential interaction with Liver Disease.
The recommended dosage of pemigatinib should be reduced in patients with severe hepatic dysfunction. No dose adjustment is recommended for patients with mild or moderate hepatic impairment.
Moderate:
Rescriptor
The delavirdine in Rescriptor has a moderate potential interaction with Liver Disease.
Delavirdine is primarily metabolized by the liver. Patients with liver disease may be at greater risk for toxicities and adverse effects from delavirdine due to decreased drug clearance. Therapy with delavirdine should be administered cautiously in patients with liver disease.
Renal Dysfunction
Moderate:
pemigatinib
Pemigatinib has a moderate potential interaction with Renal Dysfunction.
The recommended dosage of pemigatinib should be reduced in patients with severe renal disease. No dose adjustment is recommended for patients with mild or moderate renal impairment, or those patients with end-stage renal disease receiving intermittent hemodialysis.
Visual Defect/Disturbance
Moderate:
pemigatinib
Pemigatinib has a moderate potential interaction with Visual Defect/Disturbance.
Pemigatinib can cause retinal pigment epithelial detachment (RPED), which may cause symptoms such as blurred vision, visual floaters, or photopsia. A comprehensive ophthalmological examination including an optical coherence tomography should be performed prior to treatment initiation. Patients with visual disturbances should be closely monitored.
Report options
More resources
pemigatinib
A total of 307 drugs are known to interact with pemigatinib.
- Pemigatinib is in the drug class multikinase inhibitors.
- Pemigatinib is used to treat the following conditions:
Rescriptor
A total of 538 drugs are known to interact with Rescriptor.
- Rescriptor is in the drug class NNRTIs.
- Rescriptor is used to treat HIV-1 Infection.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.